Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AMAG Pharmaceuticals Inc issues FY 2014 revenue guidance below analysts' estimates


Thursday, 6 Feb 2014 07:00am EST 

AMAG Pharmaceuticals Inc:Expects FY 2014 revenue to be in the range of $88 mln and $100 mln (not including the potential milestone payment for broad IDA approval in the E.U.).Expects FY 2014 revenue of $108 mln - Thomson Reuters I/B/E/S.